Phoenix Molecular Designs secured $2M venture funding led by Pallasite Ventures with participation of new and existing angel investors
Feldan Therapeutics secured Series C financing with GC Holdings, Stonebridge Ventures, Anges Québec Capital, members of Anges Québec, and existing investors
Ampersand Capital Partners, in partnership with NEOMED-LABS management, acquired NEOMED-LABS Inc. from its not-for-profit founder and parent, the NEOMED Institute
New Water Capital acquired Brockville's Trillium Health Care Products, a premier contract manufacturer of category-leading OTC products for pharmaceutical companies.
Chinova Bioworks secured seed funding from DSM Venturing BV, Rhapsody Venture Partners, AgFunder and Natural Products Canada.
BDC Capital and VIMAC Ventures backed Angiochem secured $7.5 million Series C financing
Profound Medical (TSX: PRN; OTCQX: PRFMF) secured $18.75 million term loan agreement with the CIBC Innovation Banking
Emblem (TSX-V: EMC; OTCPK: EMMBF) signed a non-binding Letter of Intent to acquire Natura Naturals in a cash-stock deal valued at $76M (inclusive of shares already owned by Emblem).
Cambrex (NYSE: CBM) to acquire Halo Pharma from SK Capital Partners and Mohd Asif for US $425 million.
Inversago Pharma secured $7M Series A funding from Genesys Capital, Amorchem, JDRF T1D Fund, Accel-Rx, Anges Québec Capital, Anges Québec, Tarnagulla Ventures and angel investors.
Thornhill Medical secured Series A with Yonghua Investment Management Co., Ltd. 上海湧鏵投資管理有限公司
Privateer Holdings' Tilray priced its initial public offering (IPO) at US $17 per share, above its proposed price range for gross proceeds of US $153 million